BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34313512)

  • 1. Experts' review: the emerging roles of romiplostim in immune thrombocytopenia (ITP).
    Chen F; McDonald V; Newland A
    Expert Opin Biol Ther; 2021 Nov; 21(11):1383-1393. PubMed ID: 34313512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia.
    Lozano ML; Godeau B; Grainger J; Matzdorff A; Rodeghiero F; Hippenmeyer J; Kuter DJ
    Expert Rev Hematol; 2020 Dec; 13(12):1319-1332. PubMed ID: 33249935
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
    Podstawka J; Wall E; Bolster L; Patterson JM; Goodyear MD; Rydz N; Sun HL
    Thromb Res; 2022 Dec; 220():5-11. PubMed ID: 36257098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia.
    Kuter DJ; Tarantino MD; Lawrence T
    Blood Rev; 2021 Sep; 49():100811. PubMed ID: 33781612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
    Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J
    J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic ITP in routine clinical practice in central and Eastern Europe: an analysis of the PLATON study.
    Skopec B; Sninska Z; Tzvetkov N; Ivanushkin V; Björklöf K; Hippenmeyer J; Mihaylov G
    Hematology; 2021 Dec; 26(1):497-502. PubMed ID: 34238136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.
    Červinek L; Mayer J; Doubek M
    Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia.
    Grainger JD; Kühne T; Hippenmeyer J; Cooper N
    Ann Hematol; 2021 Sep; 100(9):2143-2154. PubMed ID: 34308495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
    Lozano ML; Mingot-Castellano ME; Perera MM; Jarque I; Campos-Alvarez RM; González-López TJ; Carreño-Tarragona G; Bermejo N; Lopez-Fernandez MF; de Andrés A; Valcarcel D; Casado-Montero LF; Alvarez-Roman MT; Orts MI; Novelli S; Revilla N; González-Porras JR; Bolaños E; Rodríguez-López MA; Orna-Montero E; Vicente V
    Sci Rep; 2019 Nov; 9(1):16680. PubMed ID: 31723222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of immune thrombocytopenia during pregnancy with thrombopoietin receptor agonists.
    Rottenstreich A; Bussel JB
    Br J Haematol; 2023 Dec; 203(5):872-885. PubMed ID: 37830251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
    Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
    Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romiplostim: a review of its use in immune thrombocytopenia.
    Keating GM
    Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
    Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P
    Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
    Kikuchi K; Miyakawa Y; Ikeda S; Sato Y; Takebayashi T
    BMC Health Serv Res; 2015 Jan; 15():2. PubMed ID: 25609557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.